Overview

Bioequivalence Study for Mejoral 500 Product

Status:
Completed

Trial end date:
2015-08-19

Target enrollment:

Participant gender:

Summary

This will be a monocentric, single blinded, randomized, single-dose, two-periods, two-sequence, crossover bioequivalence study of two oral formulations in healthy participants under fasting conditions.

Phase:

N/A

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Acetaminophen